首页> 外文期刊>Universal Journal of Public Health >An Open-label Randomized Clinical Study to Compare the Effects of a Nutritional Supplement versus Vitamin E on Fibroscan Score in Nonalcoholic Steatohepatitis (NASH) Patients
【24h】

An Open-label Randomized Clinical Study to Compare the Effects of a Nutritional Supplement versus Vitamin E on Fibroscan Score in Nonalcoholic Steatohepatitis (NASH) Patients

机译:开放标签的随机临床研究,比较营养补充剂和维生素E对非酒精性脂肪性肝炎(NASH)患者纤维扫描评分的影响

获取原文
           

摘要

Background: Despite the benefit of lifestyle changes, there is no standard treatment for Fibrotic NASH. However the concept of reversibility of liver fibrosis and cirrhosis with various natural biologically active compounds and antioxidant micro-nutrients is not new. Aim: The aim of this study was to compare effectiveness of Viusid~(?) (a nutritional supplement) and Vitamin E in reducing steatosis and liver fibrosis score in patients with fibrotic NASH. Methods: 52 patients diagnosed with nondiabetic and noncirrhotic NASH on liver fibroscan were divided into 2 groups randomly and given Viusid~(?) 3 sachets daily to 25 patients or Vitamin E 800 IU daily to 27 patients along with a hypocaloric diet and exercise for 3 months. Results: After 3 months treatment with Viusid~(?), as compared with Vitamin E, was associated with a significant reduction of both mean steatosis score (CAP value reduces from 286±16.3 to 208±18.5 dB/m in Viusid~(?) group vs. from 278±14.4 to 253±12.1 dB/m in Vitamin E group; p<0.00001) and fibrosis score (E value reduces from 6.8±0.5 to 5.1±0.7 kPa in Viusid~(?) group vs. from 6.9±0.5 to 6.5±0.4 kPa in Vitamin E group; p 0.00001). Conclusions: Viusid~(?) was superior to Vitamin E in reducing steatosis & fibrosis score in nondiabetic and noncirrhotic NASH patients. However, further large scale trial is needed to better assess the value of Viusid~(?) for fibrotic NASH management.
机译:背景:尽管改变生活方式有好处,但纤维化NASH尚无标准治疗方法。但是,肝纤维化和肝硬化与各种天然生物活性化合物和抗氧化剂微量营养素的可逆性概念并不新鲜。目的:本研究的目的是比较Viusid〜(?)(一种营养补品)和维生素E在降低纤维化NASH患者脂肪变性和肝纤维化评分方面的有效性。方法:将52例经肝纤维化检查诊断为非糖尿病和非肝硬化性NASH的患者随机分为两组,每天给予3袋Viusid〜(?)25例,或给予维生素E 800 IU每天27例,并同时进行低热量饮食和运动3。几个月。结果:与维生素E相比,用Viusid〜(?)治疗3个月后,平均脂肪变性评分均显着降低(CAP值从Viusid〜(?)从286±16.3降至208±18.5 dB / m。 )组与维生素E组从278±14.4 dB / m降至253±12.1 dB / m; p <0.00001)和纤维化评分(Viusid〜(?)组的E值从6.8±0.5降至5.1±0.7 kPa与维生素E组为6.9±0.5至6.5±0.4 kPa; P = 0.00001)。结论:Viusid〜(?)在降低非糖尿病和非肝硬化NASH患者的脂肪变性和纤维化评分方面优于维生素E。然而,还需要进一步的大规模试验,以更好地评估Viusid〜(?)对于纤维化NASH管理的价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号